Search

The root of evil: pre-leukemic clones that survive chemotherapy are linked to a higher risk of leukemia recurrence

Jun 10 2016 Posted in Press releases

Acute myeloid leukemia (AML) is an aggressive form of blood cancer. Treatment with intensive chemotherapy often leads to a period of freedom from overt disease called a remission. However, recurrence of the disease is common.

Position of EHA on Clinical Trials

Jul 01 2013 Posted in Advocacy news

The challenge
In Europe, the number of clinical trials is steadily decreasing. From 2007 to 2010, their number has decreased by some 20 percent from 5,028 to 4,193.

EHA launches Global Hematology Professionals’ Survey – make your voice heard

Mar 27 2023 Posted in Press releases

The Hague (Netherlands), March 27, 2023.

Adding elotuzumab to standard treatment for multiple myeloma significantly reduced the risk of disease progression, with benefits sustained at two years

Jun 12 2015

ELOQUENT-2, which evaluated elotuzumab in combination with lenalidomide and dexamethasone, is the first Phase III study to demonstrate the benefit of directly activating the immune system in the treatment of patients with relapsed or refractory multiple myeloma.

EHA and EMBL-EBI are launching CBTH

Jun 02 2022 Posted in Press releases

The Hague, May 2022 - The European Hematology Association (EHA) and the EMBL’s European Bioinformatics Institute (EMBL-EBI) are launching a new mentoring program, Computational Biology Training in Hematology (CBTH), this June.

European registry on inherited platelet disorders project, February 2025

A project update from Prof Paolo Gresele. We successfully completed the CRF harmonization phase and are now in the process of finalizing and launching the registry platform.